Skip to main content
Log in

Daratumumab for refractory warm autoimmune hemolytic anemia

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Jäger U, Barcellini W, Broome CM, Gertz MA, Hill A, Hill QA, Jilma B, Kuter DJ, Michel M, Montillo M, Röth A, Zeerleder SS, Berentsen S (2019) Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the first international consensus meeting. Blood Rev 100648:100648. https://doi.org/10.1016/j.blre.2019.100648

    Article  CAS  Google Scholar 

  2. Chen M, Zhuang J, Yang C, Zhang L, Wang W, Cai H, Yu Y, Li J, Zhou D, Han B (2020) Rapid response to a single-dose rituximab combined with bortezomib in refractory and relapsed warm autoimmune hemolytic anemia. Ann Hematol. https://doi.org/10.1007/s00277-020-03976-w

  3. Fadlallah J, Michel M, Crickx E, Limal N, Costedoat N, Malphettes M, Fieschi C, Galicier L, Oksenhendler E, Godeau B, Audia S, Mahévas M (2019) Bortezomib and dexamethasone, an original approach for treating multi-refractory warm autoimmune haemolytic anaemia. Br J Haematol 187:124–128

    Article  CAS  Google Scholar 

  4. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071–3076

    CAS  PubMed  Google Scholar 

  5. Dimopoulos MA, Orlowski RZ, Facon T, Sonneveld P, Anderson KC, Beksac M, Benboubker L, Roddie H, Potamianou A, Couturier C, Feng H, Ataman O, van de Velde H, Richardson PG (2015) Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma. Haematologica. 100:100–106

    Article  CAS  Google Scholar 

  6. Jain A, Ramasamy K (2020) Evolving role of Daratumumab: from backbencher to a frontline agent. Clin Lymphoma Myeloma Leuk. https://doi.org/10.1016/j.clml.2020.03.010

  7. Schuetz C, Hoenig M, Moshous D, Weinstock C, Castelle M, Bendavid M, Shimano K, Tolbert V, Schulz AS, Dvorak CC (2018) Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation. Blood Adv 2:2550–2553

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ankur Jain.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

Authors state that the article follows the guidelines of Helsinki and that the material has not been submitted to any other journal for publication.

Consent for publication

Authors state that consent was obtained from the patient prior to submission of the article for publication.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jain, A., Gupta, D.K. Daratumumab for refractory warm autoimmune hemolytic anemia. Ann Hematol 100, 1351–1353 (2021). https://doi.org/10.1007/s00277-020-04063-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-020-04063-w

Navigation